Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
02 09 2022
02 09 2022
Historique:
received:
27
02
2022
revised:
03
05
2022
accepted:
09
06
2022
pubmed:
15
6
2022
medline:
9
9
2022
entrez:
14
6
2022
Statut:
ppublish
Résumé
The objectives of this study were (i) to explore whether differences in cell proliferation may help explain why most high-grade serous ovarian cancers (HGSOC) arise in the fallopian tube fimbriae (FTF) rather than in ovarian cortical inclusion cysts (CIC); (ii) to compare premenopausal and postmenopausal FTF proliferation as a reason why the age incidence of HGSOC increases at a slower rate after menopause; and (iii) to compare FTF proliferation in cycling women and women using the levonorgestrel intrauterine contraceptive system (Lng-IUS) to see whether proliferation on the Lng-IUS was lower. We studied 60 women undergoing a salpingo-oophorectomy. We used Ki67, paired-box gene 8 (PAX8, Müllerian marker), and calretinin (mesothelial marker) to study FTF and CIC proliferation. FTF Ki67%+ was greater in the follicular than in the luteal phase (4.9% vs. 1.5%; P = 0.003); postmenopausal Ki67%+ was 1.7%. Ki67%+ in PAX8 negative (PAX8-) CICs was extremely low. Proliferation in PAX8+ CICs did not vary by menstrual phase or menopausal status. Follicular Ki67%+ was 2.6-fold higher in FTF than PAX8+ CICs. FTF Ki67%+ from 10 women using the Lng-IUS was not lower than in cycling women. Overall FTF Ki67%+ is greater than overall CIC Ki67%+. Overall FTF Ki67%+ in postmenopausal women is lower than in premenopausal women. The Lng-IUS is not associated with lower FTF Ki67%+. Ki67%+ provides an explanation of the preponderance of FTF-derived HGSOCs, and of the slower increase of HGSOCs after menopause. The Lng-IUS may not be associated with a protective effect against HGSOCs.
Sections du résumé
BACKGROUND
The objectives of this study were (i) to explore whether differences in cell proliferation may help explain why most high-grade serous ovarian cancers (HGSOC) arise in the fallopian tube fimbriae (FTF) rather than in ovarian cortical inclusion cysts (CIC); (ii) to compare premenopausal and postmenopausal FTF proliferation as a reason why the age incidence of HGSOC increases at a slower rate after menopause; and (iii) to compare FTF proliferation in cycling women and women using the levonorgestrel intrauterine contraceptive system (Lng-IUS) to see whether proliferation on the Lng-IUS was lower.
METHODS
We studied 60 women undergoing a salpingo-oophorectomy. We used Ki67, paired-box gene 8 (PAX8, Müllerian marker), and calretinin (mesothelial marker) to study FTF and CIC proliferation.
RESULTS
FTF Ki67%+ was greater in the follicular than in the luteal phase (4.9% vs. 1.5%; P = 0.003); postmenopausal Ki67%+ was 1.7%. Ki67%+ in PAX8 negative (PAX8-) CICs was extremely low. Proliferation in PAX8+ CICs did not vary by menstrual phase or menopausal status. Follicular Ki67%+ was 2.6-fold higher in FTF than PAX8+ CICs. FTF Ki67%+ from 10 women using the Lng-IUS was not lower than in cycling women.
CONCLUSIONS
Overall FTF Ki67%+ is greater than overall CIC Ki67%+. Overall FTF Ki67%+ in postmenopausal women is lower than in premenopausal women. The Lng-IUS is not associated with lower FTF Ki67%+.
IMPACT
Ki67%+ provides an explanation of the preponderance of FTF-derived HGSOCs, and of the slower increase of HGSOCs after menopause. The Lng-IUS may not be associated with a protective effect against HGSOCs.
Identifiants
pubmed: 35700017
pii: 704894
doi: 10.1158/1055-9965.EPI-22-0217
pmc: PMC9444882
mid: NIHMS1817505
doi:
Substances chimiques
Contraceptive Agents
0
Ki-67 Antigen
0
Levonorgestrel
5W7SIA7YZW
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1823-1829Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA181923
Pays : United States
Informations de copyright
©2022 American Association for Cancer Research.
Références
Fertil Steril. 2019 Oct;112(4 Suppl1):e93-e115
pubmed: 31623748
Steroids. 2003 Nov;68(10-13):879-90
pubmed: 14667980
Science. 1990 Aug 31;249(4972):970-1
pubmed: 2136249
Fertil Steril. 1985 Apr;43(4):554-9
pubmed: 3987924
Appl Immunohistochem Mol Morphol. 2014 Jul;22(6):401-15
pubmed: 24185118
Lancet. 2008 Jan 26;371(9609):303-14
pubmed: 18294997
Gynecol Oncol. 2003 Aug;90(2):491
pubmed: 12893227
Clin Cancer Res. 2012 Nov 15;18(22):6199-207
pubmed: 22967960
J Pathol. 2007 Jan;211(1):26-35
pubmed: 17117391
Adv Anat Pathol. 2006 Jan;13(1):1-7
pubmed: 16462151
Endocr Relat Cancer. 2010 Sep 23;17(4):R263-71
pubmed: 20870686
BMJ. 2018 Sep 26;362:k3609
pubmed: 30257920
Clin Endocrinol (Oxf). 1982 Dec;17(6):529-36
pubmed: 6819901
Obstet Gynecol. 2016 May;127(5):828-836
pubmed: 27054934
Gynecol Oncol. 2014 Feb;132(2):322-7
pubmed: 24355484
Lancet. 1971 Jul 17;2(7716):163
pubmed: 4104488
Histopathology. 2018 Apr;72(5):766-776
pubmed: 29197096
Gynecol Oncol. 2007 Feb;104(2):331-7
pubmed: 17064757
Mod Pathol. 2011 Nov;24(11):1488-99
pubmed: 21701538
Contraception. 2010 Jun;81(6):474-80
pubmed: 20472113
Am J Surg Pathol. 2006 Feb;30(2):230-6
pubmed: 16434898
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):601-10
pubmed: 19190154
J Clin Oncol. 2008 Nov 10;26(32):5284-93
pubmed: 18854563
Hum Pathol. 2015 Jul;46(7):948-56
pubmed: 26079312
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
Int J Gynecol Pathol. 2010 May;29(3):203-11
pubmed: 20407318
Epidemiology. 2020 May;31(3):402-408
pubmed: 32028322
PLoS One. 2010 Apr 26;5(4):e10358
pubmed: 20436685
Am J Obstet Gynecol. 1975 Mar 1;121(5):688-94
pubmed: 1115171
Epidemiology. 2005 Jul;16(4):508-15
pubmed: 15951669
Gynecol Oncol. 2008 Sep;110(3):452-4
pubmed: 18603285
J Chronic Dis. 1987;40 Suppl 2:59S-69S
pubmed: 3667868
Br J Cancer. 2015 Mar 31;112(7):1257-65
pubmed: 25742479
Hum Reprod. 1998 Nov;13(11):3114-20
pubmed: 9853867
Cancer Res. 1990 Dec 1;50(23):7415-21
pubmed: 2174724
Contraception. 2012 Oct;86(4):345-9
pubmed: 22402256
Int J Gynecol Pathol. 2015 Jan;34(1):3-8
pubmed: 25473746
Oncogene. 2010 Feb 25;29(8):1103-13
pubmed: 19935705
Clin Chem Lab Med. 2006;44(7):883-7
pubmed: 16776638
Gynecol Oncol. 2018 Apr;149(1):127-132
pubmed: 29482839
Nat Rev Cancer. 2017 Jan;17(1):65-74
pubmed: 27885265
Int J Cancer. 2017 Jun 1;140(11):2451-2460
pubmed: 28257597
Fertil Steril. 2008 Nov;90(5):2008.e5-8
pubmed: 18353321